

David Ritchie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1115046/publications.pdf>

Version: 2024-02-01

169
papers

3,425
citations

236833

25
h-index

168321

53
g-index

172
all docs

172
docs citations

172
times ranked

6429
citing authors

#	ARTICLE	IF	CITATIONS
1	C<scp>entreâ€based</scp> comparison of double versus single prevention strategy on transfusionâ€transmitted cytomegalovirus</scp> in <scp>atâ€risk</scp> haemopoietic stem cell transplant patients and a state survey on cytomegalovirus<scp>â€seronegative</scp> ordering practises. Internal Medicine Journal, 2023, 53, 717-722.	0.5	0
2	Clinical features, pathophysiology, and therapy of poor graft function postâ€allogeneic stem cell transplantation. Blood Advances, 2022, 6, 1947-1959.	2.5	21
3	Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). European Journal of Haematology, 2022, 108, 342-353.	1.1	3
4	Exercise in allogeneic bone marrow transplantation: a qualitative representation of the patient perspective. Supportive Care in Cancer, 2022, 30, 5389-5399.	1.0	4
5	The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. Bone Marrow Transplantation, 2022, 57, 982-989.	1.3	3
6	Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. Oncoimmunology, 2022, 11, .	2.1	7
7	Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. Blood Advances, 2022, 6, 4949-4966.	2.5	16
8	Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leukemia and Lymphoma, 2021, 62, 1482-1489.	0.6	10
9	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia, 2021, 35, 2220-2231.	3.3	20
10	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. Leukemia, 2021, 35, 2076-2085.	3.3	28
11	A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood, 2021, 137, 1970-1979.	0.6	32
12	Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.. Journal of Clinical Oncology, 2021, 39, 7560-7560.	0.8	4
13	Myeloma natural killer cells are exhausted and have impaired regulation of activation. Haematologica, 2021, 106, 2522-2526.	1.7	8
14	People With Hematological Malignancies Treated With Bone Marrow Transplantation Have Improved Function, Quality of Life, and Fatigue Following Exercise Intervention: A Systematic Review and Meta-Analysis. Physical Therapy, 2021, 101, .	1.1	20
15	An atypical case of Epsteinâ€Barr virusâ€positive plasma cell postâ€transplant lymphoproliferative disorder successfully treated with adoptive cell therapy. British Journal of Haematology, 2021, 195, 140-143.	1.2	0
16	T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone Marrow Transplantation, 2021, 56, 2857-2859.	1.3	7
17	Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study. , 2021, , .		0
18	Feasibility of early-commencing group-based exercise in allogeneic bone marrow transplantation: the BOOST study. Bone Marrow Transplantation, 2021, 56, 2788-2796.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Australia and New Zealand Transplant and Cellular Therapies <scp>COVIDâ€19</scp> vaccination consensus position statement. Internal Medicine Journal, 2021, 51, 1321-1323.	0.5	6
20	Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers. Scientific Reports, 2021, 11, 19056.	1.6	7
21	Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients. Frontiers in Immunology, 2021, 12, 749094.	2.2	5
22	Dynamics of Epsteinâ€Barr virus on postâ€transplant lymphoproliferative disorders after antithymocyte globulinâ€conditioned allogeneic hematopoietic cell transplant. Transplant Infectious Disease, 2021, 23, e13719.	0.7	3
23	Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 2303-2305.	0.6	0
24	Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution. Blood, 2021, 138, 1323-1323.	0.6	0
25	Oromandibular parafunction in chronic graftâ€versusâ€host disease: novel association and treatment approach. Internal Medicine Journal, 2021, 51, 1950-1953.	0.5	3
26	An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia. Blood, 2021, 138, 368-368.	0.6	1
27	Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control. Blood, 2021, 138, 255-255.	0.6	0
28	Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence. Journal of Translational Medicine, 2021, 19, 473.	1.8	11
29	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. Frontiers in Immunology, 2021, 12, 780442.	2.2	42
30	The development of a home-based therapeutic platform for multiple myeloma. Expert Review of Hematology, 2021, , 1-7.	1.0	0
31	Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. Internal Medicine Journal, 2021, 51, 89-117.	0.5	21
32	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica, 2020, 105, e76-e79.	1.7	37
33	Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 185-188.	0.6	2
34	New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation. Internal Medicine Journal, 2020, 50, 277-284.	0.5	12
35	Altitude exposure as a training & iron overload management strategy post leukemia. Journal of Science and Medicine in Sport, 2020, 23, 75-81.	0.6	2
36	Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1172-1174.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 2153.	2.2	16
38	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. <i>British Journal of Haematology</i> , 2020, 191, 806-815.	1.2	7
39	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2252-2261.	2.0	6
40	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.	2.5	14
41	Impact of age, cancer, and treatment-driven inflammation on T cell function and immunotherapy. <i>Journal of Leukocyte Biology</i> , 2020, 108, 953-965.	1.5	15
42	Poor graft function, a significant and emerging clinical challenge post allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 2786-2787.	0.6	0
43	Association between P2X7 Polymorphisms and Post-Transplant Outcomes in Allogeneic Haematopoietic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3772.	1.8	7
44	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	0.8	107
45	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020, 55, 1706-1715.	1.3	66
46	Utility of clinical comprehensive genomic characterization for diagnostic categorization in patients presenting with hypocellular bone marrow failure syndromes. <i>Haematologica</i> , 2020, 106, 64-73.	1.7	14
47	Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement. <i>Internal Medicine Journal</i> , 2020, 50, 774-775.	0.5	3
48	Diagnostic evaluation and considerations in hypocellular bone marrow failure: A focus on genomics. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 82-89.	0.7	4
49	Effects of chemotherapy agents used to treat pediatric acute lymphoblastic leukemia patients on bone parameters and longitudinal growth of juvenile mice. <i>Experimental Hematology</i> , 2020, 82, 1-7.	0.2	3
50	A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability. <i>British Journal of Haematology</i> , 2020, 190, e297-e301.	1.2	14
51	Severity of mucositis during allogeneic transplantation impacts post-transplant cyclosporin absorption. <i>Bone Marrow Transplantation</i> , 2020, 55, 1857-1859.	1.3	1
52	Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants. <i>Leukemia and Lymphoma</i> , 2020, 61, 1257-1259.	0.6	2
53	Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). <i>BMJ Open</i> , 2020, 10, e034629.	0.8	26
54	High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation. <i>Blood</i> , 2020, 136, 13-14.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.. Journal of Clinical Oncology, 2020, 38, TPS8075-TPS8075.	0.8	0
56	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: An international, multicenter propensity matched study.. Journal of Clinical Oncology, 2020, 38, 8021-8021.	0.8	0
57	Study protocol of a pilot study evaluating feasibility and acceptability of a psychosexual intervention for couples postallogeneic haematopoietic stem cell transplantation. BMJ Open, 2020, 10, e039300.	0.8	0
58	An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation. Blood, 2020, 136, 36-37.	0.6	1
59	A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC). Blood, 2020, 136, 34-35.	0.6	4
60	Significant EBV Reactivation Is Associated with Poorer Overall Survival Due to Increased NRM Post Myeloablative/Reduced Intensity, T-Cell Deplete Allogeneic Stem Cell Transplant for MDS or Acute Leukaemia. Blood, 2020, 136, 27-27.	0.6	0
61	A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up. Blood, 2020, 136, 51-52.	0.6	0
62	Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 18-19.	0.6	0
63	Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 7-8.	0.6	0
64	Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study. Blood, 2020, 136, 40-42.	0.6	0
65	Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 25-26.	0.6	1
66	Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study. Blood, 2020, 136, 26-27.	0.6	1
67	Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 175-189.	1.3	6
68	Acute myeloid leukaemia presenting with diabetes insipidus. Internal Medicine Journal, 2019, 49, 785-788.	0.5	4
69	Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?. Journal of Oncology, 2019, 2019, 1-18.	0.6	5
70	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology, 2019, 37, 253-260.	0.8	5
71	Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 2019, 186, e56-e60.	1.2	9
72	Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape. Leukemia and Lymphoma, 2019, 60, 1908-1916.	0.6	3

#	ARTICLE	IF	CITATIONS
73	Pediatric aplastic anemia treatment patterns and responses; power in the numbers. <i>Haematologica</i> , 2019, 104, 1909-1912.	1.7	3
74	Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes. <i>Cell Death and Differentiation</i> , 2019, 26, 1516-1530.	5.0	10
75	Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study. <i>Blood</i> , 2019, 134, 1523-1523.	0.6	10
76	Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 368-368.	0.6	7
77	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , 2019, 134, 756-756.	0.6	24
78	Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE [®] (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 833-833.	0.6	55
79	Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial). <i>Blood</i> , 2019, 134, 251-251.	0.6	3
80	Impact of Pre-Engraftment Cytomegalovirus Viraemia in Allogeneic Haematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2019, 134, 5656-5656.	0.6	0
81	Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels. <i>Blood</i> , 2019, 134, 5662-5662.	0.6	0
82	The Economic and Health Utilization Cost of Clinically Significant Cytomegalovirus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3437-3437.	0.6	2
83	Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. <i>Blood</i> , 2019, 134, 5328-5328.	0.6	1
84	Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse. <i>Blood</i> , 2019, 134, 4044-4044.	0.6	1
85	Mechanisms of Action and Clinical Development of Elotuzumab. <i>Clinical and Translational Science</i> , 2018, 11, 261-266.	1.5	23
86	Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate/high-dose cytarabine. <i>European Journal of Haematology</i> , 2018, 101, 174-184.	1.1	9
87	Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1490-1496.	2.0	29
88	Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. <i>Internal Medicine Journal</i> , 2018, 48, 276-285.	0.5	13
89	A hospital and home-based exercise program to address functional decline in people following allogeneic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2018, 26, 1727-1736.	1.0	18
90	Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia. <i>Journal of Immunological Methods</i> , 2018, 463, 97-104.	0.6	4

#	ARTICLE	IF	CITATIONS
91	The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients. <i>Annals of Hematology</i> , 2018, 97, 2509-2518.	0.8	5
92	P2X7 polymorphisms and stem cell mobilisation. <i>Leukemia</i> , 2018, 32, 2724-2726.	3.3	9
93	Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316). <i>Blood</i> , 2018, 132, 205-205.	0.6	2
94	Providing Diagnoses in Bone Marrow Failure Syndromes through Multimodal Comprehensive Genomic Evaluation and Multidisciplinary Care: The Melbourne Genomics Health Alliance Bone Marrow Failure Flagship. <i>Blood</i> , 2018, 132, 3867-3867.	0.6	0
95	miRNA expression profiling of cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2017, 126, 1131-1139.	0.9	55
96	Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 840-844.	2.0	10
97	Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 870-877.	1.3	21
98	Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2017, 215, 1684-1694.	1.9	61
99	COMPARISON OF INNATE IMMUNITY CHANGES FOLLOWING IBRUTINIB AND VENETOCLAX TREATMENT OF RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA. <i>Hematological Oncology</i> , 2017, 35, 385-386.	0.8	4
100	Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1961-1967.	2.0	56
101	Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. <i>Leukemia and Lymphoma</i> , 2017, 58, 89-95.	0.6	11
102	Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 1506.	2.2	13
103	A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3557-3557.	0.8	17
104	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. <i>Oncotarget</i> , 2017, 8, 41620-41630.	0.8	1
105	Spontaneous onset and transplant models of the V κ *MYC mouse show immunological sequelae comparable to human multiple myeloma. <i>Journal of Translational Medicine</i> , 2016, 14, 259.	1.8	21
106	CIK immunotherapy in refractory hematologic malignancies. <i>Leukemia Research</i> , 2016, 49, 60-61.	0.4	2
107	Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3540-3547.	1.3	19
108	Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen Recognition. <i>Immunity</i> , 2016, 44, 32-45.	6.6	169

#	ARTICLE	IF	CITATIONS
109	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	0.6	17
110	Building a Targeted Approach to Assess Risk of Anthracycline Induced Cardiomyopathy Amongst Paediatric Cancer Patients. <i>Blood</i> , 2016, 128, 5280-5280.	0.6	0
111	Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management. <i>Internal Medicine Journal</i> , 2015, 45, 702-710.	0.5	11
112	The rise and rise of advanced practice nursing. <i>Internal Medicine Journal</i> , 2015, 45, 691-693.	0.5	4
113	Author reply. <i>Internal Medicine Journal</i> , 2015, 45, 1316-1316.	0.5	0
114	Practical management of myelofibrosis with ruxolitinib. <i>Internal Medicine Journal</i> , 2015, 45, 1221-1230.	0.5	7
115	CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. <i>Cancer Immunology Research</i> , 2015, 3, 483-494.	1.6	103
116	Lack of durable disease control with chemotherapy for mycosis fungoides and S�zary syndrome: a comparative study of systemic therapy. <i>Blood</i> , 2015, 125, 71-81.	0.6	181
117	Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in Thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with Thymoglobulin GVHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2015, 50, 566-572.	1.3	3
118	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. <i>Journal of Clinical Investigation</i> , 2015, 125, 2077-2089.	3.9	111
119	Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. <i>Oncolmmunology</i> , 2015, 4, e1038011.	2.1	4
120	MicroRNA as potential biomarkers in Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 237-248.	1.4	47
121	CAR-T cells are serial killers. <i>Oncolmmunology</i> , 2015, 4, e1053684.	2.1	14
122	A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 242-249.	2.0	3
123	Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2939-2939.	0.6	10
124	Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4237-4237.	0.6	2
125	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015, 126, 832-832.	0.6	90
126	The Frequency of Cytomegalovirus (CMV)-Specific CD8+ T Cells Distinguishes CMV Clinical Outcomes Following Hematopoietic Allogeneic Stem Cell Transplant: A Prospective Multicentre Cohort Study. <i>Blood</i> , 2015, 126, 4312-4312.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia. <i>Blood</i> , 2015, 126, 2599-2599.	0.6	0
128	CAR-T Cells Are Serial Killers of Tumor Cells. <i>Blood</i> , 2015, 126, 3088-3088.	0.6	0
129	Outcomes following second allogeneic haematopoietic transplants using fludarabine+melfhalan conditioning. <i>Bone Marrow Transplantation</i> , 2014, 49, 852-853.	1.3	0
130	Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2014, 4, e237-e237.	2.8	3
131	Fludarabine Melphalan reduced-intensity conditioning allotransplantation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. <i>Bone Marrow Transplantation</i> , 2014, 49, 17-23.	1.3	14
132	The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 291-296.	0.2	12
133	Editorial overview: Tumour immunology: New frontiers in cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2014, 27, vii-x.	2.4	0
134	Allogeneic transplantation as anticancer immunotherapy. <i>Current Opinion in Immunology</i> , 2014, 27, 38-45.	2.4	22
135	The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. <i>Nature Immunology</i> , 2014, 15, 431-438.	7.0	410
136	The passive+aggressive relationship between CLL-B cells and T cell immunity. <i>Leukemia Research</i> , 2014, 38, 1160-1161.	0.4	4
137	Natural killer T cells: drivers or passengers in preventing human disease?. <i>Nature Reviews Immunology</i> , 2014, 14, 640-646.	10.6	58
138	Screening with Spirometry Is a Useful Predictor of Later Development of Noninfectious Pulmonary Syndromes in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 781-786.	2.0	25
139	The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound. <i>Cell Reports</i> , 2014, 7, 1009-1019.	2.9	34
140	Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia + a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse. <i>Blood</i> , 2014, 124, 1927-1927.	0.6	2
141	Causes and Effects of Methotrexate Dose Alterations in Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2460-2460.	0.6	2
142	Intravenous Immunoglobulin Post Allogeneic Stem Cell Transplantation Is Associated with Lower Levels of CMV Reactivation. <i>Blood</i> , 2014, 124, 2482-2482.	0.6	0
143	Choice of Conditioning Regimen Influences Risk of Thymoglobulin Infusion Reactions in Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 5840-5840.	0.6	0
144	Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia. <i>Molecular Therapy</i> , 2013, 21, 2122-2129.	3.7	361

#	ARTICLE	IF	CITATIONS
145	Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations. <i>Blood</i> , 2013, 122, 2143-2143.	0.6	0
146	Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?. <i>Oncolmmunology</i> , 2012, 1, 372-374.	2.1	13
147	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. <i>Blood</i> , 2011, 117, 1605-1613.	0.6	152
148	Drug-mediated and cellular immunotherapy in multiple myeloma. <i>Immunotherapy</i> , 2010, 2, 243-255.	1.0	13
149	The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 331-334.	0.6	42
150	Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. <i>Haematologica</i> , 2009, 94, 1618-1622.	1.7	75
151	A New Therapeutic Target for Leukemia Comes to the Surface. <i>Cell</i> , 2009, 138, 226-228.	13.5	12
152	Is allogeneic stem cell transplantation for transformed follicular lymphoma anti-lymphoma stem cell therapy?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1852-1853.	0.6	2
153	Complete molecular response of e6a2 BCR-ABL ⁺ positive acute myeloid leukemia to imatinib then dasatinib. <i>Blood</i> , 2008, 111, 2896-2898.	0.6	25
154	Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).. <i>Blood</i> , 2008, 112, 1696-1696.	0.6	19
155	The Frequency, Manifestations and Duration of Prolonged Cytopenias after First Line Fludarabine-Combination Chemotherapy for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 3176-3176.	0.6	2
156	The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study. <i>Blood</i> , 2008, 112, 3596-3596.	0.6	5
157	The Level of Glycolytic Metabolism of AML Blasts May Predict Drug Sensitivity and Prognosis in Patients with AML. <i>Blood</i> , 2008, 112, 4022-4022.	0.6	0
158	Gene-Modified CD8+ T Cells Undergo Functional Polarization to Effector and Central Memory Cells in Response to Antigen Exposure.. <i>Blood</i> , 2008, 112, 1531-1531.	0.6	0
159	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. <i>Blood</i> , 2008, 112, 3900-3900.	0.6	7
160	Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 402-403.	4.3	1
161	Plasma cell lysate as an antigen source in multiple myeloma immunotherapy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1894-1895.	0.6	2
162	The role of second autografts in the treatment of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 847-848.	0.6	4

#	ARTICLE	IF	CITATIONS
163	Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.. Blood, 2007, 110, 1167-1167.	0.6	9
164	In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunology, Immunotherapy, 2006, 56, 155-163.	2.0	55
165	Resting B Cells Suppress CD8+ T Cell Function and Prevent the Induction of Graft Versus Host Disease.. Blood, 2005, 106, 3111-3111.	0.6	0
166	Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2005, 106, 5499-5499.	0.6	0
167	Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biology of Blood and Marrow Transplantation, 2003, 9, 435-442.	2.0	22
168	Aplastic anemia as a late complication of thymoma in remission. European Journal of Haematology, 2002, 68, 389-391.	1.1	24
169	Predictors and Outcomes of Dose Reduction of Methotrexate and Cyclosporin <scp>Graftâ€Versusâ€Hostâ€Disease</scp> Prophylaxis Following Allogeneic Haematopoietic Cell Transplantation. Internal Medicine Journal, 0, , .	0.5	0